Our Mission
We believe that systemic exposure to drugs, especially in dermatology, should be an exception. Our mission is to develop localized treatment options that match the efficacy of the best systemic drugs with the safety of local, topical administration
MEET OUR TEAM
Marina Shevachman, Ph.D. Sr. Director, Product Development
Marina has 15+ years of experience in drug development, commercial manufacturing, and expanding product portfolio. She has a wide experience in drug product submission with a proven record of FDA approvals. She joined the CAGE Bio team in 2018. Prior to joining CAGE Bio, she held senior-level scientist positions at Perrigo and Allergan.
Chase Corley, M.S. Scientist II, Product Development
Chase brings 10+ years of analytical chemistry and molecular biology research to the Research and Development team. Prior to joining CAGE Bio, he worked at UT Southwestern Medical Center researching sterol analytical chemistry in the Lipidomics Core Facility for Molecular Genetics. He received his M.S. from the University of North Texas in Biochemistry and Molecular Biology.
Jason Mars, M.S. Scientist I, Product Development
Jason brings 6+ years of experience with analytical
chemistry, commercial manufacturing, and product
formulation. Prior to joining CAGE Bio, Jason worked
with Alcon Pharmaceuticals and BioChroma Analytical
Labs developing analysis techniques, performing FDA
clinical investigations as an expert witness, and advising
on new pharmaceutical ventures as a consultant with the
Gerson Lehrman Group.
Elaine Campbell, M.S. Sr. Scientist, Product Development
Elaine joined CAGE Bio’s R&D team in March 2024, bringing 15+ years of molecular biology and assay development expertise. She holds an M.S. in Biotechnology from Stephen F. Austin State University. Previously, she worked at Alcon Laboratories on assay development and biomarker identification for Dry Eye disease, led early-phase biotherapeutics research at Boehringer Ingelheim, and guided ophthalmic formulation development at Novartis Pharmaceuticals.
Drew Sturtevant, Ph.D. Senior Scientist, Associate Director, Product Development
Dr. Sturtevant is an experienced analytical biochemist and molecular geneticist. He helps lead the development of CAGE Bio's CGB-500 and is an active member and advocate of the DFW life-science ecosystem. He received his Ph.D. from the University of North Texas and completed his Post-Doctoral training at UTSW Medical Center.
Luis Ponce Chinea, Scientist I
Luis Ponce Chinea brings over five years of industry experience
spanning biologics manufacturing, MSAT, and small molecule R&D.
Beginning his career in large molecule manufacturing — including monoclonal antibodies, cell and gene therapies, and vaccines — Luis transitioned into small molecule formulation and process development, where he has spent the past three years driving innovative solutions
in topical drug delivery. He has contributed to the successful commercialization of multiple products, both NDAs and ANDAs,
while completing graduate studies at Northeastern University.
Jaylen Mans, Contractor
Jaylen joined the CAGE Bio team in August 2025. Jaylen brings 7+ years of analytical and pharmaceutical chemistry experience with expertise
in drug formulation, liquid chromatography, and solid-state characterization methods. Jaylen received his Ph.D. from the University of North Texas Health Science Center, where his research focused on developing
novel drug delivery systems to enhance the bioavailability of BCS
class II and class IV compounds.
Patricia Oto, RPh, Quality and Regulatory Lead
Patti has 25+ years of executive leadership experience with regulatory and quality oversight. Prior to joining CAGE Bio, Patti served as the Senior Vice President of Regulatory Affairs and Quality Assurance at Chrono Therapeutics. She has held positions at Incline Therapeutics (acquired by The Medicines Company), Onyx Pharmaceuticals (Amgen), Corgentech (Anesiva), Coulter (Corixa, GlaxoSmithKline), Genentech (Roche), and Syntex. Patti has worked on global regulatory submissions in several therapeutic areas.
Shashwati Godbole, M.S. PMP, Program Manager
Shashwati joined CAGE Bio bringing in research and industry experience within the Medical Affairs Operations and Management space. She received her M.S. in Biotechnology from Northeastern University. Prior to joining CAGE Bio, she worked at Vertex Pharmaceuticals primarily supporting MSLs and product management teams along with congress planning, grants and external fundings.
Welcome! Latest updates inside.
CAGE Bio Announces Start of Double-Blind Vehicle-Controlled Clinical Trial of Novel Topical DNA Aptamer Therapy CGB-600 for Vitiligo Treatment